Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...
What Is It, and Why Does It Matter? Tzield (teplizumab-mzwv) is a prescription immune therapy that can help delay the progression of type 1 diabetes (T1D). The FDA has approved Tzield for slowing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results